Abstract
Numerous therapeutic advances in the management of diabetes have been made in recent years, leading to the 2023 update of the Société francophone du diabète's position paper. These new treatments, for both autoimmune type 1 and type 2 diabetes, will continue to develop, offering patients personalized care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
